Annovis Bio

Annovis Bio’s Buntanetap Trial for Alzheimer’s Disease Gets Green Light from DSMB: A Positive Step Forward

BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS), a biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases, recently announced a significant milestone in its clinical trial journey. The …

Annovis Bio’s Buntanetap Trial for Alzheimer’s Disease Gets Green Light from DSMB: A Positive Step Forward Read More

dementia, alzheimer disease

Pennsylvania Department of Aging Hosts 2023 ADRD Virtual Forum, Highlights Lewy Body and Frontotemporal Dementias

PENNSYLVANIA — On Thursday, the Pennsylvania Department of Aging held its annual Alzheimer’s Disease and Related Disorders (ADRD) Virtual Forum. The forum, which attracted over 400 attendees, serves to educate, …

Pennsylvania Department of Aging Hosts 2023 ADRD Virtual Forum, Highlights Lewy Body and Frontotemporal Dementias Read More
Annovis Bio

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study

BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS)recently announced that the independent statistical group concluded that its Phase 2/3 AD study was sufficiently powered to continue as originally planned without …

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study Read More